GLP-1 drugs like Ozempic and Mounjaro have significant health benefits for type 1 diabetes, including weight loss, despite ...

This resulted in seven deaths and multiple injuries to various people, again, because of the inaccuracy in a specific set of ...

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

Abbott has launched Libre Assist, a feature within the Libre app designed to help people living with diabetes better understand how the foods they eat affect their glucose levels.

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers ...

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...

Insulet PODD is well-poised to grow in the coming quarters due to the strength of its Omnipod 5 platform. The company is strongly executing against its long-term priorities to drive penetration, ...

Introduction Optimising glycaemic control in type 1 diabetes (T1D) remains challenging. Flash glucose monitoring with FreeStyle Libre 2 (FSL2) is a novel alternative to the current standard of care ...

Some FreeStyle Libre 3 plus glucose monitor sensors may provide incorrect low glucose readings, Health Canada said in an alert. Abbott Diabetes Care recalled certain types of its FreeStyle Libre 3 and ...

Patients are being warned to stop using some glucose monitors made by Abbott Diabetes Care after the company found malfunctioning sensors may be linked to hundreds of adverse events and several deaths ...

The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...